Inter Pharma
Inter Pharma Co., Ltd., commonly referred to as Inter Pharma, is a leading player in the pharmaceutical industry, headquartered in Thailand (TH). Established in 1993, the company has made significant strides in the development and distribution of high-quality pharmaceutical products across Southeast Asia. Specialising in a diverse range of therapeutic areas, Inter Pharma focuses on innovative solutions that cater to both chronic and acute health conditions. Their core offerings include prescription medications, over-the-counter products, and nutraceuticals, all distinguished by rigorous quality standards and a commitment to research and development. With a strong market presence, Inter Pharma has achieved notable milestones, including partnerships with international organisations and a robust distribution network. This positions the company as a trusted name in the healthcare sector, dedicated to improving patient outcomes through effective and accessible treatments.
DitchCarbon Score
How does Inter Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Inter Pharma's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Inter Pharma's reported carbon emissions
In 2022, Inter Pharma reported total carbon emissions of approximately 3,251,000 kg CO2e. This figure includes 567,880 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 2,630,270 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, Scope 3 emissions accounted for about 53,120 kg CO2e, which includes all other indirect emissions that occur in the value chain. Despite the significant emissions reported, there are currently no specific reduction targets or climate pledges disclosed by Inter Pharma. The company has not outlined any initiatives under the Science Based Targets initiative (SBTi) or other formal reduction commitments. As such, their climate strategy remains unclear within the context of industry standards for emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 567,880 |
| Scope 2 | 2,630,270 |
| Scope 3 | 53,120 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Inter Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
